CAMRF (Camurus AB) EPS without NRI: $1.21 (TTM As of Mar. 2026)


CAMRF Camurus AB CAMRF
83 GF Score
Price $54.00
GF Value $69.05
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Camurus AB EPS without NRI?

Camurus AB CAMRF -3.57% 83 EPS without NRI is $1.21 as of Mar. 2026. GuruFocus rates CAMRF with a GF Score™ of 83/100 and a GF Value™ of $69.05 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,172 Biotechnology companies, Camurus AB ranks better than 99.15% on this metric.

Camurus AB's earnings per share without non-recurring items for the three months ended in Mar. 2026 was $0.26. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $1.21.

During the past 12 months, Camurus AB's average earnings per share (NRI) Growth Rate was 23.70% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 140.90% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Camurus AB's EPS without NRI or its related term are showing as below:

CAMRF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -46.4   Med: 12.1   Max: 140.9
Current: 140.9

During the past 13 years, Camurus AB's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 140.90% per year. The lowest was -46.40% per year. And the median was 12.10% per year.

CAMRF's 3-Year EPS without NRI Growth Rate is ranked better than
99.15% of 1172 companies
in the Biotechnology industry
Industry Median: 16.8 vs CAMRF: 140.90

Camurus AB's EPS (Diluted) for the three months ended in Mar. 2026 was $0.26. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $1.21.

Camurus AB's EPS (Basic) for the three months ended in Mar. 2026 was $0.26. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $1.22.


Camurus AB  (OTCPK:CAMRF) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Camurus AB EPS without NRI Related Terms


Camurus AB EPS without NRI Historical Data

* Premium members only.

The historical data trend for Camurus AB's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Camurus AB EPS without NRI Chart

Camurus AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.18 0.09 0.73 0.66 1.32

Camurus AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.33 0.43 0.34 0.18 0.26

CAMRF vs VRTX, REGN, ALNY: EPS without NRI Comparison

For the Biotechnology subindustry, Camurus AB's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Camurus AB PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Camurus AB's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Camurus AB's PE Ratio without NRI falls into.


CAMRF
83GF Score
Camurus AB CAMRF
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Camurus AB EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $1.21 mean?
Camurus AB (CAMRF) has a EPS without NRI of $1.21 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Camurus AB and its competitors. According to the industry distribution chart, Camurus AB ranks #10 out of 1172 companies in the Biotechnology industry, placing it in the top 0.90000000000001%.
Is Camurus AB's EPS without NRI too high?
Camurus AB's current EPS without NRI is $1.21. The Biotechnology industry median EPS without NRI is 16.80. Camurus AB's value of $1.21 is 92.8% below this industry median. Based on the distribution chart, Camurus AB ranks #10 out of 1172 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Camurus AB has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #10 out of 1172 companies for EPS without NRI. This places Camurus AB in the top 1% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 16.80. Camurus AB's value of $1.21 is 92.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.80, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camurus AB's current EPS without NRI of $1.21 is 92.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Camurus AB and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camurus AB's current EPS without NRI is $1.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Modestly Undervalued. The stock's GF Value™ is $69.05, compared to a current price of $54.00 — trading 21.8% below its estimated fair value. The current EPS without NRI is $1.21 and 92.8% below the Biotechnology industry median of 16.80. Camurus AB's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Camurus AB (CAMRF), the current EPS without NRI is $1.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Camurus AB (CAMRF) Overvalued in 2026?

Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued. The current stock price of $54.00 is trading 21.8% below its estimated GF Value™ of $69.05. GuruFocus considers Camurus AB to be Modestly Undervalued.

Key valuation signals for CAMRF:

  • EPS without NRI: $1.21
  • GF Value™: $69.05 vs. price of $54.00 (21.8% below fair value)
  • GF Score™: 83/100 with 1 warning sign
  • Industry Position: 92.8% below the Biotechnology median (#10 of 1172)

No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Camurus AB Business Description

Address Rydbergs torg 4, Lund, SWE, SE-224 84
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
83GF Score

Get the complete analysis for CAMRF

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$54.00
Price
$69.05
GF Value